Stockholders’ Equity (Details) - USD ($) $ / shares in Units, $ in Thousands |
1 Months Ended | 12 Months Ended | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
Nov. 08, 2021 |
Jan. 01, 2021 |
Oct. 07, 2020 |
Jan. 31, 2018 |
Sep. 01, 2017 |
Jul. 31, 2022 |
Jul. 31, 2021 |
Jul. 31, 2020 |
Dec. 31, 2014 |
Jan. 31, 2011 |
|
| Stockholders’ Equity (Details) [Line Items] | ||||||||||
| Common stock, par value (in Dollars per share) | $ 0.01 | $ 0.01 | ||||||||
| Percentage of commission payable on equity offering | 3.00% | |||||||||
| Maximum offering price under sales agreement | $ 20,000 | $ 20,000 | ||||||||
| Shares of common stock settlements (in Shares) | 332,700 | 237,383 | 208,537 | 333,265 | ||||||
| Contribution obligation | $ 875 | $ 814 | $ 780 | |||||||
| Contribution obligation | $ 814 | 780 | $ 839 | |||||||
| Shares of common stock as employee compensation (in Shares) | 4,167 | |||||||||
| Common stock as employee compensation | $ 10 | |||||||||
| Common stock available for grant, description | The amendment and restatement of the Amended and Restated 2011 Plan was for purposes of, among other things, (i) increasing the shares of common stock available for grant under the Amended and Restated 2011 Plan by an additional 4,000,000 shares of common stock bringing the total number of shares available for grant to 9,000,000 shares of common stock and (ii) extending the term of the Amended and Restated 2011 Plan until October 7, 2030. | |||||||||
| Common stock granted (in Shares) | 4,142,000 | |||||||||
| Purchase of common stock (in Shares) | 700,000 | |||||||||
| Restricted stock units RSU (in Shares) | 260,000 | |||||||||
| Outstanding options vested and exercisable | $ 68 | 488 | 0 | |||||||
| Intrinsic value of options outstanding | 193 | 1,323 | 79 | |||||||
| Intrinsic value of options exercised | $ 4 | $ 38 | $ 0 | |||||||
| Remaining PSUs awarded Expired | 3 years | |||||||||
| Performance share, description | During the fiscal years ended 2020 and 2019, the Company awarded additional PSUs to its executive officers. These awards provide for the grant of shares of our common stock at the end of a three–year period based on the achievement of revenue growth and adjusted EBITDA growth goals met at threshold, target or maximum levels over the respective period. For the fiscal year ended July 31, 2022, the Company reversed net total PSU accruals of $124 for a former officer who forfeited 25,300 and 20,000 PSUs from the fiscal 2020 and fiscal 2019 awards, respectively, resulting in net PSU compensation expense of $70. For the fiscal year ended July 31, 2021, the Company accrued compensation expense of $272 for the outstanding PSUs awarded during fiscal 2020 and 2019 as the achievement of certain growth goals was deemed probable at that time. During fiscal 2021, a former officer forfeited 4,000 PSUs awarded in fiscal 2019. During the fiscal year 2020, no compensation expense was recognized as the achievement of the growth goals was deemed not probable at that time. During fiscal 2020, a former executive forfeited 10,500 PSUs from the fiscal 2019 award. | |||||||||
| Restricted stock units, description | The Company awarded restricted stock units (“RSUs”) to our CEO who was appointed in November 2021. The award was for 260,000 RSUs which vest over three years on the anniversary of his hiring. The fair market value of these RSUs at the date of grant was $881. The Company awarded to its 3 independent directors 117,189 RSUs in April 2022 which vest over two years whose fair market value was $300. In July 2022 the Company awarded to its 3 independent directors 124,998 RSUs which vest in one year and whose fair market value was $300. During fiscal 2022, the Company recognized shared based compensation expense of $295 for these RSUs. | |||||||||
| Unrecognized compensation | $ 3,835 | |||||||||
| Weighted average remaining life of approximately | 2 years | |||||||||
| 2011 Plan [Member] | ||||||||||
| Stockholders’ Equity (Details) [Line Items] | ||||||||||
| Share based compensation arrangement by share based payment award restricted stock units (in Shares) | 3,000,000 | |||||||||
| Share-based compensation arrangement by share-based payment award, number of additional shares authorized (in Shares) | 2,000,000 | |||||||||
| Common stock available for grants (in Shares) | 5,000,000 | |||||||||
| Common Stock [Member] | ||||||||||
| Stockholders’ Equity (Details) [Line Items] | ||||||||||
| Authorized common stock that may be issued and sold under sales agreement | $ 19,200 | |||||||||
| Securities that may be sold under the agreement | $ 150,000 | |||||||||